Loading...
01/09 23:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates a negative sentiment due to a 12% revenue decline, reduced gross margins, and a significant adjusted EBITDA loss. Despite improvements in service margins and new partnerships, the ongoing financial challenges and restructuring issues overshadow positive developments. The lack of shareholder return discussion further weakens the outlook. Given these factors, the stock price is likely to experience a negative movement in the short term.
Consolidated Revenue $9.3 million, a decrease of $1.3 million or 12% year-over-year. The decline was due to shedding certain lines of business, macroeconomic uncertainty, and slow global sales of capital equipment with increased pricing pressure.
Security Services Revenue Increased by 10% year-over-year due to increased project work related to the airport security maintenance business.
Gross Margin Percentage for Product Sales 44% versus 52% year-over-year, an 8% decrease. This was due to lower manufacturing utilization caused by supply chain challenges related to magnets, which were resolved in Q4.
Gross Margin Percentage for Security Services 14% versus 15% year-over-year, a 1% decrease. Improvements in scheduling, logistics, and management of overtime and on-call hours are expected to improve margins further.
Adjusted EBITDA Loss of $2,000 versus a profit of $545,000 year-over-year. The loss was primarily due to a drop in Scientific Equipment sales.
Net Loss $1.5 million, an improvement of $144,000 year-over-year. The improvement was due to lower depreciation from the impairment of an acquired intangible asset in 2024 and the cessation of recording losses from associates due to the impairment of the Quad investment in 2024.
OEM and licensing agreement with IMRIS: Partnership with Siemens-affiliated IMRIS for intraoperative MRI applications, showcasing the application of core magnetic resonance technology in areas like spinal cord surgery.
Partnership with United States Pharmacopeia: Formal method publication for excipients used in pharmaceuticals, enhancing drug delivery mechanisms.
Integration with Wiley's KnowItAll: Benchtop NMR libraries integrated with Wiley's scientific software and databases, expanding product utility.
Focus on proprietary technologies: Shift away from reselling Agilent and Mediso equipment to focus on proprietary products, with increased investment in marketing and sales.
Partnerships in service business: Collaborations with Liberty Defense (U.S.) and LINEV Systems (U.K.) to enhance service offerings.
Supply chain resolution: Resolved supply chain challenges related to magnets from China, ensuring a stronger supply chain.
Service business improvements: New management led by Marc Tomlinson improved gross margins from 6% in Q1 to double digits in Q3, with further improvements expected.
Restructuring sales organization: Efforts to improve sales organization domestically and globally, addressing past challenges.
Discontinuation of certain business lines: Exited reselling of Agilent and Mediso equipment to focus on proprietary technologies, impacting short-term revenue but expected to benefit long-term growth.
Revenue Decline: The company reported a 12% decrease in consolidated revenue compared to the same period in 2024, attributed to discontinuation of certain business lines and macroeconomic uncertainty. Capital equipment sales were slow globally, with increased pricing pressure.
Gross Margin Reduction: Gross margin percentage for product sales dropped from 52% in Q3 2024 to 44% in Q3 2025 due to lower manufacturing utilization and supply chain challenges related to magnets. Although resolved in Q4, this impacted Q3 performance.
Adjusted EBITDA Loss: The company reported an adjusted EBITDA loss of $2,000 in Q3 2025, compared to a profit of $545,000 in Q3 2024, primarily due to a decline in scientific equipment sales.
Net Loss: Net loss for Q3 2025 was $1.5 million, an improvement from the prior year but still a significant loss, reflecting ongoing financial challenges.
Supply Chain Challenges: The company faced supply chain disruptions related to magnets sourced from China, which affected manufacturing and product availability in Q3 2025.
Sales Organization Restructuring: The company acknowledged ongoing challenges in restructuring its sales organization, which has been a recurring issue affecting performance.
Unsuccessful Acquisition: The acquisition of K'Prime, intended to enhance market channel access, did not meet expectations, requiring renewed efforts in this area.
Global Economic Uncertainty: Global uncertainty, particularly in capital equipment sales, negatively impacted the company’s performance, with effects seen in both domestic and international markets.
Focus on proprietary technologies: The company has discontinued reselling Agilent and Mediso equipment to focus on its proprietary products. This is expected to positively influence future performance as resources are invested in marketing and sales for proprietary products.
Service business margin improvements: The company expects continued improvement in gross margins for the service business, with positive results anticipated in Q4 2025 due to better scheduling, logistics, and management practices.
Partnerships in the service business: New partnerships with Liberty Defense and LINEV Systems are expected to enhance the service business's performance.
OEM and licensing agreement with IMRIS: The company announced an agreement with IMRIS, a Siemens-affiliated company, for intraoperative MRI applications, validating the core magnetic resonance technology's applicability to new areas.
Supply chain improvements: Supply chain challenges related to magnets from China have been resolved, and the company expects a stronger supply chain going forward.
Integration with Wiley's KnowItAll: The integration of Benchtop NMR libraries with Wiley's KnowItAll software is expected to enhance the product's utility and market reach.
The selected topic was not discussed during the call.
The earnings call indicates a negative sentiment due to a 12% revenue decline, reduced gross margins, and a significant adjusted EBITDA loss. Despite improvements in service margins and new partnerships, the ongoing financial challenges and restructuring issues overshadow positive developments. The lack of shareholder return discussion further weakens the outlook. Given these factors, the stock price is likely to experience a negative movement in the short term.
The earnings call reveals a mixed financial performance with a significant drop in mining margins and a net loss, despite debt reduction efforts. The strategic shift to HPC presents growth potential, but current challenges such as supply chain issues and macroeconomic pressures overshadow this. The Q&A section lacks clarity on management's responses, adding to uncertainty. The absence of dividends and a negative adjusted EBITDA further dampen sentiment. Thus, the stock price is likely to experience a negative movement in the short term.
The earnings call reveals several concerning factors: decreased revenue and mining profit due to Bitcoin halving, regulatory challenges, and a significant impairment charge. Despite some positive aspects like debt repayment and cost reduction, the Q&A section highlights management's vague responses regarding future financial contributions and lack of dividend plans. The equity raise and cash balance are insufficient to offset these negatives. Therefore, the overall sentiment is negative, suggesting a potential stock price decline of -2% to -8% over the next two weeks.
The earnings call presents several concerns: a decrease in revenue and mining profit, ongoing debt obligations, and challenging market conditions for Bitcoin miners. The equity raise may dilute shares, and the lack of dividend plans could disappoint investors. Although there are cost reductions and debt repayments, the Q&A reveals uncertainties in growth strategies and unclear timelines for financial improvement. These factors, combined with a cautious outlook on mining economics and no new partnerships, suggest a negative sentiment, likely leading to a stock price decrease of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
